TCTMD

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Just 7% of HFrEF patients received quadruple therapy, and even in this group, the absolute risk of events at 1 year was high.
The Manila Times

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy t…

Cytokinetics is committed to supporting patients with MYQORZO & You™, a personalized program for patients prescribed MYQORZO ...

Cytokinetics, Incorporated: Cytokinetics Announces MYQORZO (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...
Endovascular Today

Pulmonary Embolism Risk Stratification: Progress, Gaps, and the Path Forward

Pulmonary embolism (PE) is a common and potentially life-threatening condition with presentations ranging from mild symptoms to circulatory collapse. Early and accurate risk stratification is ...

Massive runaway stars in the Milky Way: Observational study explores origins and ejection process

Researchers from the Institute of Cosmos Sciences of the University of Barcelona (ICCUB) and the Institute of Space Studies of Catalonia (IEEC), in collaboration with the Institute of Astrophysics of ...
The Manila Times

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HC…

with the Disease, Inspired by the Experience with HCM of ...

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, ...